Ophthalmic surgery, lasers & imaging retina · 2025
Association of National Eye Institute Visual Function Questionnaire 39 Scores With Visual Function in Age-related Macular Degeneration Over 24 Months.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yao Catherine S, Lue Victoria, Stinnett Sandra S, Luhmann Ulrich F O, Lad Eleonora M
Аннотация
BACKGROUND AND OBJECTIVE: The aim of this study was to determine the National Eye Institute Visual Function Questionnaire 39 (NEI-VFQ39) score association with visual function (VF) tests in early (eAMD) and intermediate (iAMD) age-related macular degeneration.
PATIENTS AND METHODS: Thirty-three eAMD, 47 iAMD, 21 control subjects completed the NEIVFQ39 at baseline and 22 eAMD, 31 iAMD, 17 control subjects at 24 months. Best-corrected visual acuity (BCVA), low luminance visual acuity (LLVA), cone contrast test (CCT), microperimetry (MP) with eye-tracking (MAIA), and dark adaptation (DA) testing were administered during both visits.
RESULTS: At baseline and 24 months, iAMD patients scored lower NEI-VFQ39 composite scores than eAMD participants and controls (P < 0.05); longitudinal changes showed no differences between groups. Baseline composite scores were associated with LLVA (Spearman-r = 0.33, P < 0.001), percent-reduced threshold (PRT) (r = -0.33, P = 0.001), and absolute threshold (AT) (r = 0.31, P = 0.003) on MP.
CONCLUSION: Although the NEI-VFQ39 did not detect change over 24 months, these results support the use of NEI-VFQ39 as a cross-sectional tool in iAMD.
PATIENTS AND METHODS: Thirty-three eAMD, 47 iAMD, 21 control subjects completed the NEIVFQ39 at baseline and 22 eAMD, 31 iAMD, 17 control subjects at 24 months. Best-corrected visual acuity (BCVA), low luminance visual acuity (LLVA), cone contrast test (CCT), microperimetry (MP) with eye-tracking (MAIA), and dark adaptation (DA) testing were administered during both visits.
RESULTS: At baseline and 24 months, iAMD patients scored lower NEI-VFQ39 composite scores than eAMD participants and controls (P < 0.05); longitudinal changes showed no differences between groups. Baseline composite scores were associated with LLVA (Spearman-r = 0.33, P < 0.001), percent-reduced threshold (PRT) (r = -0.33, P = 0.001), and absolute threshold (AT) (r = 0.31, P = 0.003) on MP.
CONCLUSION: Although the NEI-VFQ39 did not detect change over 24 months, these results support the use of NEI-VFQ39 as a cross-sectional tool in iAMD.